ストックスクリーナーアプリを入手
6.14
2.38%
-0.15
前日終値:
$6.29
開ける：
$6.3
24時間の取引高:
469.19K
Relative Volume:
0.49
時価総額：
$446.76M
収益：
-
当期純損益:
$-119.87M
株価収益率:
-3.3923
EPS:
-1.81
ネットキャッシュフロー:
$-109.90M
1週間 パフォーマンス:
-12.66%
1か月 パフォーマンス:
-21.68%
6か月 パフォーマンス:
-42.35%
1年 パフォーマンス:
-55.35%
1日の値動き範囲:
$6.00
$6.30
1週間の範囲:
$5.78
$7.42
52週間の値動き範囲:
$5.78
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
名前
Oric Pharmaceuticals Inc
セクター
電話
(650) 388-5600
住所
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
ORIC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
6.14 | 446.76M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-31 | 開始されました | Wells Fargo | Overweight |
| 2024-09-06 | 開始されました | Stifel | Buy |
| 2024-02-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 開始されました | Wedbush | Outperform |
| 2023-03-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-16 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 再開されました | Oppenheimer | Perform |
| 2022-04-04 | アップグレード | Citigroup | Neutral → Buy |
| 2022-03-25 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-03-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-03-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-07-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-01-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-13 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-06 | アップグレード | Citigroup | Neutral → Buy |
| 2020-08-03 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-19 | 開始されました | Citigroup | Neutral |
| 2020-05-19 | 開始されました | Guggenheim | Buy |
| 2020-05-19 | 開始されました | JP Morgan | Overweight |
| 2020-05-19 | 開始されました | Jefferies | Buy |
すべてを表示
Oric Pharmaceuticals Inc (ORIC) 最新ニュース
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by Analysts - MarketBeat
Charles Schwab Investment Management Inc. Purchases 7,726 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC stock touches 52-week low at $6.31 amid market challenges By Investing.com - Investing.com South Africa
ORIC stock touches 52-week low at $6.31 amid market challenges - Investing.com Australia
PNC Financial Services Group Inc. Buys 2,520 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical - GlobeNewswire
Breakthrough: Novel Prostate Cancer Drug Demonstrates Powerful Two-Pronged Attack Strategy - StockTitan
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9%Time to Sell? - MarketBeat
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
Wedbush Reaffirms Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% – Here’s What Happened - Defense World
(ORIC) Investment Report - Stock Traders Daily
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Victory Capital Management Inc. - Defense World
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth - TipRanks
(ORIC) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC's Latest Employee Stock Grants: Key Details on Compensation Package - StockTitan
Rhumbline Advisers Purchases 4,072 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
ORIC Pharmaceuticals (ORIC) Projected to Post Earnings on Monday - MarketBeat
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World
ORIC Pharmaceuticals Reports Progress in Cancer Trials - TipRanks
Wedbush Expects Increased Earnings for ORIC Pharmaceuticals - MarketBeat
ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% After Analyst Upgrade - MarketBeat
(ORIC) Investment Analysis and Advice - Stock Traders Daily
ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 - Defense World
ORIC Pharmaceuticals’ (ORIC) Buy Rating Reiterated at Guggenheim - Defense World
Wedbush Equities Analysts Lift Earnings Estimates for ORIC - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% on Analyst Upgrade - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 at JPMorgan Chase & Co. - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Buy" Rating from Guggenheim - MarketBeat
Oric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114 - TipRanks
ORIC® Pharmaceuticals Announces Focused Registrational - GlobeNewswire
Can ORIC Pharmaceuticals' Extended Cash Runway Fuel Success in Cancer Drug Development? - StockTitan
Wedbush Reduces Earnings Estimates for ORIC Pharmaceuticals - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Earnings Beat - MarketBeat
HC Wainwright Reaffirms Buy Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - Defense World
Wedbush Predicts Weaker Earnings for ORIC Pharmaceuticals - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Oric Pharmaceuticals Inc (ORIC) 財務データ
収益
当期純利益
現金流量
EPS
Oric Pharmaceuticals Inc (ORIC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
115,615 |
| Piscitelli Dominic | Chief Financial Officer |
Dec 16 '24 |
Sale |
8.28 |
8,851 |
73,298 |
106,764 |
| Multani Pratik S | Chief Medical Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
55,615 |
| Multani Pratik S | Chief Medical Officer |
Dec 16 '24 |
Sale |
8.28 |
8,850 |
73,293 |
46,765 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 15 '24 |
Option Exercise |
0.00 |
67,000 |
0 |
803,308 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 16 '24 |
Sale |
8.28 |
24,660 |
204,214 |
778,648 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):